<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="8D60A454-72C5-A9B8-D13F-B211813E35AC" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title ID="INV-dee3b552-c9e2-48ea-8712-6acd23d8fb1e" mediaType="text/x-hl7-title+xml">ENLON-PLUS (edrophonium chloride, USP and
        atropine sulfate, USP) Injection<br />Rx only </title>
<effectiveTime value="20060309" />
<setId root="bdeb47eb-e538-498d-ae98-14d5db29eab0" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Baxter Healthcare Corporation</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="E6E168F1-E648-8006-AA8D-9B944459A975" />
<effectiveTime value="20060309" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="10019-180" codeSystem="2.16.840.1.113883.6.69" />
<name>Enlon-Plus</name>
<formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="10">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="10" />
</numerator>
<denominator unit="mL" value="1">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="QO611KSM5P" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>edrophonium chloride</name>
<activeMoiety>
<activeMoiety>
<name>edrophonium</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="0.14">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="0.14" />
</numerator>
<denominator unit="mL" value="1.0">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1.0" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="03J5ZE7KA5" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>atropine sulfate</name>
<activeMoiety>
<activeMoiety>
<code code="7C0697DR9I" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>atropine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>edrophonium chloride and atropine sulfate</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<quantity>
<numerator unit="mg" value="2.0">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="2.0" />
</numerator>
<denominator unit="mL" value="1.0">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1.0" />
</denominator>
</quantity>
<inactiveIngredientSubstance>
<code code="VTK01UQK3G" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium sulfite</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium citrate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>citric acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="5">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="5" />
</numerator>
<denominator value="1.0">
<translation value="1.0" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code />
<formCode code="C43165" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="AMPULE" />
<asContent>
<quantity>
<numerator value="10">
<translation code="C48473" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="AMPULE" value="10" />
</numerator>
<denominator value="1.0">
<translation value="1.0" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="10019-180-05" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX" />
</containerPackagedMedicine>
</asContent>
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="10019-195" codeSystem="2.16.840.1.113883.6.69" />
<name>Enlon-Plus</name>
<formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="10.0">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="10.0" />
</numerator>
<denominator unit="mL" value="1.0">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1.0" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="QO611KSM5P" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>edrophonium chloride</name>
<activeMoiety>
<activeMoiety>
<name>edrophonium</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="0.14">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="0.14" />
</numerator>
<denominator unit="mL" value="1.0">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1.0" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="03J5ZE7KA5" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>atropine sulfate</name>
<activeMoiety>
<activeMoiety>
<code code="7C0697DR9I" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>atropine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>edrophonium chloride and atropine sulfate</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<quantity>
<numerator unit="mg" value="2.0">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="2.0" />
</numerator>
<denominator unit="mL" value="1.0">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1.0" />
</denominator>
</quantity>
<inactiveIngredientSubstance>
<code code="VTK01UQK3G" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium sulfite</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<quantity>
<numerator unit="mg" value="4.5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="4.5" />
</numerator>
<denominator unit="mL" value="1.0">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1.0" />
</denominator>
</quantity>
<inactiveIngredientSubstance>
<code code="339NCG44TV" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>phenol</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium citrate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>citric acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="15">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="15" />
</numerator>
<denominator value="1.0">
<translation value="1.0" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="10019-195-15" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="INV-5b2b994c-80db-42fc-bbe6-9b5a875e5af9">
<id root="771963B3-D74C-CF27-E6FB-1934320442E3" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title ID="INV-85e86764-e5e8-4c16-bf98-d347862a829f" mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text ID="INV-9d910087-4498-4400-89d1-b79ca766c538"><paragraph ID="INV-1b268bb9-ee1c-4763-9a67-b16c94743e58">ENLON-PLUS
                            (edrophonium chloride, USP and atropine sulfate, USP) Injection, for
                            intravenous use, is a sterile, nonpyrogenic, nondepolarizing
                            neuromuscular relaxant antagonist. ENLON-PLUS is a combination drug
                            containing a rapid acting acetylcholinesterase inhibitor, edrophonium
                            chloride, and an anticholinergic, atropine sulfate. Chemically,
                            edrophonium chloride is ethyl (m-hydroxyphenyl) dimethylammonium
                            chloride; its structural formula is:</paragraph><renderMultiMedia referencedObject="MM-a1a8698a-8349-49b7-9be2-543dc992a3e3" /><paragraph ID="INV-344b7a79-5439-4a34-9a75-abf793fff676">Molecular Formula:
                                C<sub>10</sub>H<sub>16</sub>ClNO</paragraph><paragraph ID="INV-2fe16ff3-1721-4e00-b082-7d3629c514c3">Molecular Weight:
                            201.70</paragraph><paragraph ID="INV-c00f550d-a017-4144-855b-cfa97a8b2760">Chemically,
                            atropine sulfate is:
                            endo-(&#177;)-alpha-(hydroxymethyl)-8-methyl-8-azabicyclo [3.2.1]oct-3-yl
                            benzeneacetate sulfate (2:1) monohydrate. Its structural formula is:</paragraph><renderMultiMedia referencedObject="MM-037e7070-d5a4-4dd3-9c5c-561944c3e284" /><paragraph ID="INV-549c68ac-359e-4a00-aa69-a2fa1f8f3a28">Molecular Formula:
                                (C<sub>17</sub>H<sub>23</sub>NO<sub>3</sub>)<sub>2</sub>&#183;H<sub>2</sub>SO<sub>4</sub>&#183;H<sub>2</sub>O</paragraph><paragraph ID="INV-75f4bbd7-3888-4bcf-b639-1dd269a00266">Molecular Weight:
                            694.84</paragraph><paragraph ID="INV-d57409f9-0da2-41ac-911c-7fad179367c9">ENLON-PLUS contains
                            in each mL of sterile solution:</paragraph><paragraph ID="INV-e2f8a36e-16d9-44c9-b67f-acf5663d712e"><content styleCode="bold">5 mL Ampuls: </content>10&#160;mg edrophonium chloride
                            and 0.14&#160;mg atropine sulfate compounded with 2.0&#160;mg sodium sulfite as a
                            preservative and buffered with sodium citrate and citric acid. The pH
                            range is 4.0-5.0.</paragraph><paragraph ID="INV-c528ed2d-258f-4e14-8bfe-d1b20f490323"><content styleCode="bold">15 mL Multidose Vials:</content> 10&#160;mg edrophonium
                            chloride and 0.14&#160;mg atropine sulfate compounded with 2.0&#160;mg sodium
                            sulfite and 4.5&#160;mg phenol as a preservative and buffered with sodium
                            citrate and citric acid. The pH range is 4.0-5.0.</paragraph></text>
<effectiveTime value="20060309" />
<component>
<observationMedia ID="MM-a1a8698a-8349-49b7-9be2-543dc992a3e3">
<value mediaType="image/jpeg"><reference value="molecular1.JPG" /></value>
</observationMedia>
</component>
<component>
<observationMedia ID="MM-037e7070-d5a4-4dd3-9c5c-561944c3e284">
<value mediaType="image/jpeg"><reference value="molecular2.JPG" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section ID="INV-4e39f95c-178a-4613-be35-30e1ca3fe4e1">
<id root="E08DC91E-73BE-A3F2-AD78-22B3DFD0848C" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title ID="INV-e679efea-eb43-4a3c-89d4-3a0f93f585fe" mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<effectiveTime value="20060309" />
<component>
<section ID="INV-1893ee47-31a0-481f-9253-402dc2a1c3e5">
<id root="7784F270-E089-6EB2-D62D-7504C8BF79AB" />
<title ID="INV-99de6283-3e39-4dad-b860-eac6f14f7959" mediaType="text/x-hl7-title+xml">Pharmacodynamics</title>
<text ID="INV-0c2d1db6-f02f-4ac4-b6af-1a1c757330a0"><paragraph ID="INV-87fdc65c-7fec-4f04-8c04-ae19b54efa65">ENLON-PLUS
                                    (edrophonium chloride, USP and atropine sulfate, USP) Injection
                                    is a combination of an anticholinesterase agent, which
                                    antagonizes the action of nondepolarizing neuromuscular blocking
                                    drugs, and a parasympatholytic (anticholinergic) drug, which
                                    prevents the muscarinic effects caused by inhibition of
                                    acetylcholine breakdown by the anticholinesterase. Edrophonium chloride antagonizes the effect of nondepolarizing neuromuscular
                                    blocking agents primarily by inhibiting or inactivating
                                    acetylcholinesterase. By inactivating the acetylcholinesterase
                                    enzyme, acetylcholine is not hydrolyzed as rapidly by
                                    acetylcholinesterase and is thereby allowed to accumulate. The
                                    greater quantity of acetylcholine reaching the sites of
                                    nicotinic cholinergic postjunctional receptors improves
                                    transmission of impulses across the myoneural junction. The
                                    concomitant, unavoidable accumulation of acetylcholine at the
                                    sites of muscarinic cholinergic transmission occurring at the
                                    parasympathetic, postganglionic receptors of the autonomic
                                    nervous system, may cause bradycardia, bronchoconstriction,
                                    increased secretions, and other parasympathomimetic side
                                    effects. The magnitude of these muscarinic side effects can be
                                    expected to vary from patient to patient depending upon the                     amount of vagal nerve activity present. Atropine sulfate
                                    counteracts these side effects.</paragraph><paragraph ID="INV-20239340-8bc6-443a-9212-d5c9e1a22eb6">Intravenous
                                    edrophonium chloride in doses of 0.5 to 1.0 mg/kg promptly
                                    antagonizes the effects of nondepolarizing muscle relaxants
                                    reaching the maximum antagonism within 1.2 minutes. A plateau of
                                    maximal antagonism is sustained for 70 minutes1. Intravenous
                                    atropine sulfate has an immediate effect on heart rate which
                                    reaches a peak in 2 to 16 minutes and lasts 170 minutes after an
                                    average 0.02 mg/kg dose.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-11ae2bf1-ec75-4318-9964-bf296de9b26f">
<id root="4725B934-27E8-73E2-5D59-EDE3EC5ED428" />
<title ID="INV-8a0372e4-88de-42ef-bb19-48c05f2a2aa9" mediaType="text/x-hl7-title+xml">Pharmacokinetics</title>
<effectiveTime value="20060309" />
<component>
<section ID="INV-0ad63ef3-d060-4329-89ae-4c7c88d9c194">
<id root="FDD1B84C-B73E-9BB8-7D1D-003B8DA965F9" />
<title ID="INV-ec5433a1-b315-4ba3-a2b2-607957ca823f" mediaType="text/x-hl7-title+xml">Edrophonium
                                        Chloride</title>
<text ID="INV-8a4622f3-355b-48a7-9763-91b91f63ffdb"><paragraph ID="INV-f6902ab0-4862-442f-a336-47f9b5237898">Edrophonium chloride given intravenously shows first
                                            order elimination in a two compartment open
                                            pharmacokinetic model3. Onset of reversal of muscle
                                            relaxant induced depression in twitch tension occurs
                                            within three minutes. Edrophonium is primarily renally
                                            excreted with 67% of the dose appearing in the urine4.
                                            Hepatic metabolism and biliary excretion have also been
                                            demonstrated in animals4,8. While infants and children
                                            have been shown to have a reduced plasma half-life and
                                            an increased clearance of edrophonium, doses in children
                                            are not significantly different from adults on a mg/kg
                                            basis although they are more variable in effect.
                                            Conversely, elderly subjects (&gt;75 years old) have
                                            a prolonged plasma half-life and a reduced clearance.
                                            Studies have shown that in spite of these changes the
                                            onset and duration of action is unchanged in these
                                            patients.</paragraph></text>
<effectiveTime value="20060309" />
<component>
<section>
<id root="5B7FC18A-E966-B24F-F333-F73C5706CFE9" />
<title ID="INV-2c2ad747-5df7-42fc-9735-4085825db3d4" mediaType="text/x-hl7-title+xml">Table of Pharmacokinetic Values for Edrophonium
                                                Chloride</title>
<text ID="INV-2140d628-d4d1-4be6-9d15-230e96b85700"><table frame="void">
<col align="left" width="300pt" />
<col align="left" width="300pt" />
<col align="left" width="300pt" />
<col align="left" width="300pt" />
<col align="left" width="300pt" />
<col align="left" width="300pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">Population</td><td align="left" valign="middle">T1/2&#223;
                                                  hr&#177;S.D.</td><td align="left" valign="middle">VD
                                                  L/kg&#177;S.D.</td><td align="left" valign="middle">Cl
                                                  mL/kg/min&#177;S.D.</td><td align="left" valign="middle">N</td><td align="left" valign="middle">Ref.</td></tr>
<tr valign="top"><td align="left" valign="middle">Adults</td><td align="left" valign="middle">1.8&#177;0.6</td><td align="left" valign="middle">1.1&#177;0.2</td><td align="left" valign="middle">9.6&#177;2.7</td><td align="left" valign="middle">10</td><td align="left" valign="middle">3</td></tr>
<tr valign="top"><td align="left" valign="middle">Anephric Patients<footnote ID="INV-8803ab49-f3f3-4020-8f9a-fd049efa7463">No adjustments of edrophonium
                                                  dosage are required because
                                                  elimination of non-depolarizing
                                                  muscle relaxants is similarly
                                                  decreased.</footnote><footnote ID="INV-2a322d85-9b94-4e8e-94d1-b17890b42bd3">Values for anephric patients
                                                  were calculated using a
                                                  non-compartmental
                                                  model.</footnote></td><td align="left" valign="middle">3.4&#177;1.0</td><td align="left" valign="middle">0.68&#177;0.13</td><td align="left" valign="middle">2.7&#177;1.4</td><td align="left" valign="middle">6</td><td align="left" valign="middle">4</td></tr>
<tr valign="top"><td align="left" valign="middle">Infants
                                                  (3 wks-11 mos)</td><td align="left" valign="middle">1.2&#177;0.5</td><td align="left" valign="middle">1.2&#177;0.2</td><td align="left" valign="middle">17.8&#177;1.2</td><td align="left" valign="middle">4</td><td align="left" valign="middle">5</td></tr>
<tr valign="top"><td align="left" valign="middle">Children (1-6 yr)</td><td align="left" valign="middle">1.6&#177;0.5</td><td align="left" valign="middle">1.2&#177;0.7</td><td align="left" valign="middle">14.2&#177;7.3</td><td align="left" valign="middle">4</td><td align="left" valign="middle">5</td></tr>
<tr valign="top"><td align="left" valign="middle">Adults</td><td align="left" valign="middle"><footnote ID="INV-f36de277-19fb-4753-8274-6ed5c2306e68">From a study using a different,
                                                  less sensitive HPLC method and
                                                  fitting C vs T data to a
                                                  biexponential
                                                  curve.</footnote>0.9&#177;0.3</td><td align="left" valign="middle">1.1&#177;0.6</td><td align="left" valign="middle">13.3&#177;5</td><td align="left" valign="middle">5</td><td align="left" valign="middle">6</td></tr>
<tr valign="top"><td align="left" valign="middle">Elderly<footnoteRef ID="INV-79494786-a88e-4d3e-ac0a-c8c2105f7117" IDREF="INV-8803ab49-f3f3-4020-8f9a-fd049efa7463" /> (over 75 yr)</td><td align="left" valign="middle"><footnoteRef ID="INV-a4f276ef-fcc2-458e-88b9-b6c813fb4eac" IDREF="INV-f36de277-19fb-4753-8274-6ed5c2306e68" /> 1.4&#177;0.3</td><td align="left" valign="middle">0.6&#177;0.1</td><td align="left" valign="middle">5.1&#177;1</td><td align="left" valign="middle">5</td><td align="left" valign="middle">6</td></tr>
</tbody>
</table><paragraph ID="INV-18a0207f-49dd-43c7-92e0-86dd47af5279">T1/2&#223;= Elimination half-life</paragraph><paragraph ID="INV-13b72adf-fe1c-4459-b72e-a976d194940d">VD= Volume of distribution</paragraph><paragraph ID="INV-19dda4fc-d191-45e3-b6f4-002bdcd442d2">Cl= Clearance</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-a156e1f1-3283-4366-b476-1fa564ff2470">
<id root="177F8117-6199-665E-8720-211668620C08" />
<title ID="INV-e1e995f0-f7ba-4be0-ad37-d0a1decfcd37" mediaType="text/x-hl7-title+xml">Atropine
                                        Sulfate</title>
<text ID="INV-aec02bb5-8f6f-4da4-9e15-a78ae2c657d2"><paragraph ID="INV-ae504ba0-2f3a-463d-b027-39147df473d7">Atropine sulfate given intravenously shows first order
                                            elimination in a two compartment open model<sup>7</sup>.
                                            Approximately 57% of a dose of atropine appears in the
                                            urine as unchanged drug. Tropine is the primary hepatic
                                            metabolite of atropine and it accounts for approximately
                                            30% of the dose<sup>2</sup>. Atropine is only 14&#177;9%
                                            bound to plasma proteins<sup>7</sup>. Atropine clearance                                      in children under 2 years old and in the elderly is                     decreased in relation to normal healthy adults.</paragraph><table frame="void"><caption ID="INV-379f1c6e-d3fe-4a30-b36f-7e5e0cb6b61c">Table of Pharmacokinetic Values for Atropine
                                                Sulfate</caption>
<col align="left" width="300pt" />
<col align="left" width="300pt" />
<col align="left" width="300pt" />
<col align="left" width="300pt" />
<col align="left" width="300pt" />
<col align="left" width="300pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">Population</td><td align="left" valign="middle">T1/2&#223; hr&#177;S.D.</td><td align="left" valign="middle">VD L/kg&#177;S.D.</td><td align="left" valign="middle">Cl
                                                  mL/kg/min&#177;S.D.</td><td align="left" valign="middle">N</td><td align="left" valign="middle">Ref.</td></tr>
<tr valign="top"><td align="left" valign="middle">Adults</td><td align="left" valign="middle">3.0&#177;0.9</td><td align="left" valign="middle">1.6&#177;0.4</td><td align="left" valign="middle">6.8&#177;2.9</td><td align="left" valign="middle">8</td><td align="left" valign="middle">7</td></tr>
<tr valign="top"><td align="left" valign="middle">Children(0.08-10 yrs)</td><td align="left" valign="middle">4.8&#177;3.5</td><td align="left" valign="middle">2.2&#177;1.5</td><td align="left" valign="middle">6.4&#177;3.9</td><td align="left" valign="middle">13</td><td align="left" valign="middle">7</td></tr>
<tr valign="top"><td align="left" valign="middle">Elderly<footnote ID="INV-bd48d297-bf72-456b-a595-ebe199af27be">No dose adjustment required because the
                                                  cardiovascular effect of atropine is
                                                  diminished in the elderly.</footnote>
                                                  (65-75 yrs)</td><td align="left" valign="middle">10.0&#177;7.3</td><td align="left" valign="middle">1.8&#177;1.2</td><td align="left" valign="middle">2.9&#177;1.9</td><td align="left" valign="middle">10</td><td align="left" valign="middle">7</td></tr>
</tbody>
</table><paragraph ID="INV-c3295599-6fa6-44df-8197-092053130a74">T1/2&#223; = Elimination half-life</paragraph><paragraph ID="INV-f7049c8d-d532-4ab6-af40-3cfbde753d9a">VD
                                            = Volume of distribution</paragraph><paragraph ID="INV-48c60959-cdd7-4e97-b222-324f82a20703">Cl
                                            = Clearance</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="INV-56b22608-25d8-4941-8b9d-b768d913a5e4">
<id root="1C97100E-95AF-2922-7A3E-06A8AF45A2B0" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE SECTION" />
<title ID="INV-5f28f999-4581-4078-a0a2-5e04f019c4df" mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text ID="INV-a0430e5b-aa21-452c-8b8c-39def3c7e848"><paragraph ID="INV-4dcf2990-e793-4f36-9d69-3e6f2d746de3">ENLON-PLUS
                            (edrophonium chloride, USP and atropine sulfate, USP) Injection is
                            recommended as a reversal agent or antagonist of nondepolarizing  neuromuscular blocking agents. It is not effective against depolarizing
                            neuromuscular blocking agents. It is also useful if used adjunctively in
                            the treatment of respiratory depression caused by curare overdosage.</paragraph><paragraph ID="INV-e0a648af-f6b6-4870-bcd7-95004d138c3d">The appropriateness
                            of the specific fixed ratio of edrophonium and atropine contained in
                            ENLON-PLUS has not been evaluated in myasthenia gravis. Therefore,
                            ENLON-PLUS is not recommended for use in the differential diagnosis of
                            this condition.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-a9676159-355d-405c-9dac-ca76a580036b">
<id root="40993211-C071-8AFF-6ADE-92C4F8777A18" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title ID="INV-a9e83062-b5af-43fd-bd19-4c8a34e182c2" mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text ID="INV-aa5c2011-5771-4e79-abfe-bc798dadb60c"><paragraph ID="INV-b50a1a7e-e26e-434a-9743-b34a48e6f22f">ENLON-PLUS
                            (edrophonium chloride, USP and atropine sulfate, USP) Injection is not
                            to be used in patients with known hypersensitivity to either of the
                            components, or in patients with intestinal or urinary obstruction of
                            mechanical type. Atropine sulfate is contraindicated in the presence of
                            acute glaucoma, adhesions (synechiae) between the iris and lens of the
                            eye, and pyloric stenosis.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-683fbcee-0779-4f93-a75f-233f4b9f83f1">
<id root="B7A8DAFF-BCAF-38B4-519D-7E3704AEA6C5" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION" />
<title ID="INV-913561ef-0a3e-4185-a05e-447095eaa404" mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text ID="INV-ccb71d9a-cff9-470e-802a-62674d791951"><paragraph ID="INV-0c799fb5-85fe-41bc-8882-e7afa4eb0b94">ENLON-PLUS
                            (edrophonium chloride, USP and atropine sulfate, USP) Injection should
                            be used with caution in patients with bronchial asthma or cardiac
                            arrhythmias. Cardiac arrest has been reported to occur in digitalized
                            patients as well as in jaundiced subjects receiving cholinesterase
                            inhibitors. In patients with cardiovascular disease, given anesthesia
                            with narcotic and nitrous oxide without a potent inhalational agent,
                            there is increased risk for clinically significant bradycardia. In
                            patients receiving beta-adrenergic blocking agents there is increased
                            risk for excessive bradycardia from unopposed parasympathetic vagal
                            tone. Such patients should receive atropine sulfate alone prior to
                            ENLON-PLUS. Isolated instances of respiratory arrest have also been
                            reported following the administration of edrophonium chloride.
                            Additional atropine sulfate (1 mg) should be available for immediate use
                            to counteract severe cholinergic reaction which may occur in
                            hypersensitive individuals when ENLON-PLUS is used.</paragraph><paragraph ID="INV-9ff3ca3a-6905-44a9-920c-cb8678db465f">ENLON-PLUS contains
                            sodium sulfite, a sulfite that may cause allergic-type reactions
                            including anaphylactic symptoms and life-threatening or less severe
                            asthmatic episodes in certain susceptible people. The overall prevalence
                            of sulfite sensitivity in the general population is unknown and probably
                            low. Sulfite sensitivity is seen more frequently in asthmatic than in
                            nonasthmatic people.</paragraph><paragraph ID="INV-aae75bb6-f92c-42c5-8700-1d78828ae89a">There is a
                            potential for tissue irritation by extravascular injection.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-6b7420f8-3ba8-45bf-9721-2e32d6c6e559">
<id root="59350719-51CD-9501-490C-B1AC05015B10" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS SECTION" />
<title ID="INV-86097660-d88c-4e6a-a8bb-b2beff8c28f9" mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<effectiveTime value="20060309" />
<component>
<section ID="INV-fa25dbf7-89f3-43a0-a3ef-d9b43d351073">
<id root="193D1818-EF5D-40A2-2EA0-753D5B81D406" />
<title ID="INV-d21e5682-c5b7-47b4-9bae-dabac83f4d1e" mediaType="text/x-hl7-title+xml">General</title>
<text ID="INV-52fc0b80-821e-49e4-a917-77dd89201210"><paragraph ID="INV-08da4873-72e7-41dc-ad22-7e0df6541700">As with any
                                    antagonist of nondepolarizing muscle relaxants, adequate
                                    recovery of voluntary respiration and neuromuscular transmission
                                    must be obtained prior to the discontinuation of respiratory
                                    assistance. Should a patient develop &#8220;anticholinesterase
                                    insensitivity&#8221; for brief or prolonged periods, the patient
                                    should be carefully monitored and the dosage of
                                    anticholinesterase drugs reduced or withheld until the patient                                 again becomes sensitive to them. Use with caution in patients
                                    with prostatic hypertrophy and in debilitated patients with
                                    chronic lung disease.</paragraph><paragraph ID="INV-ef1d9550-a91a-46ea-8ff4-53ffe9af836a">When used
                                    in therapeutic doses, atropine can cause dryness of the mouth.
                                    This effect is additive when the product is administered with
                                    other drugs that can cause dryness of the mouth.</paragraph><paragraph ID="INV-d5611db6-78c0-41e6-9409-13e7db277a43">Since
                                    atropine sulfate slows gastric emptying and gastrointestinal
                                    motility, it may interfere with the absorption of other
                                    medications. The effect of atropine on dryness of the mouth may
                                    be increased if it is given with other drugs that have
                                    anticholinergic action (tricyclic antidepressants,
                                    antipsychotics, some antihistamines, and antiparkinsonism
                                    drugs).</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-6d184979-574f-4cee-9eda-edc9787d6a4a">
<id root="5ECED25D-16D5-5DA3-3912-5BD40E9E7E88" />
<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG INTERACTIONS SECTION" />
<title ID="INV-f5cf853b-7eea-428c-b281-0dd1a965cc37" mediaType="text/x-hl7-title+xml">Drug Interactions</title>
<text ID="INV-98a6ee0e-ea99-4e8d-a143-ee77ec4f806a"><paragraph ID="INV-ca9f30b9-c6da-4ee5-bf7b-3102da674641">ENLON-PLUS
                                    (edrophonium chloride, USP and atropine sulfate, USP) Injection should not be administered prior to the administration of any
                                    nondepolarizing muscle relaxants. It should be administered with
                                    caution to patients with symptoms of myasthenic weakness who are
                                    also on anticholinesterase drugs. Anticholinesterase overdosage
                                    (cholinergic crisis) symptoms may mimic underdosage (myasthenic
                                    weakness), so the use of this drug may worsen the condition of
                                    these patients (see OVERDOSAGE section for treatment).</paragraph><paragraph ID="INV-9f85304a-9c63-40bd-9b43-a5b52efdc03d">Narcotic
                                    analgesics, except when combined with potent inhaled
                                    anesthetics, appear to potentiate the effect of edrophonium on
                                    the sinus node and conduction system, increasing both the
                                    frequency and duration of bradycardia. In patients with
                                    cardiovascular disease, given anesthesia with narcotic and
                                    nitrous oxide without a potent inhalational agent, there is   increased risk for clinically significant bradycardia. In
                                    patients receiving beta-adrenergic blocking agents there is
                                    increased risk for excessive bradycardia from unopposed
                                    parasympathetic vagal tone. Such patients should receive
                                    atropine sulfate alone prior to ENLON-PLUS.</paragraph><paragraph ID="INV-0fca5a44-3795-4adc-b8d5-56740ab2a084">Compared to
                                    muscle relaxants with some vagolytic activity, muscle relaxants
                                    with no vagolytic effects, i.e. vecuronium, may be associated                       with a slightly higher incidence of vagotonic effects such as
                                    bradycardia and first-degree heart block when reversed with
                                    ENLON-PLUS.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-f8e48293-5499-4fb3-a810-d69bf22cf05e">
<id root="61F298CB-A70C-9D51-2905-C76021E4C4E7" />
<title ID="INV-3e428ef1-2cad-49bb-99e8-4afdd56279da" mediaType="text/x-hl7-title+xml">Pregnancy Category
                                C</title>
<text ID="INV-b9e6c2f3-b140-459e-bc85-ff7dc974c397"><paragraph ID="INV-f28c4245-8ca2-4922-bfc1-cb4519f13b7b">Animal
                                    reproduction studies have not been conducted with ENLON-PLUS. It
                                    is also not known whether ENLON-PLUS can cause fetal harm when
                                    administered to a pregnant woman or can affect reproduction
                                    capacity. ENLON-PLUS should be used during pregnancy only if the          potential benefit justifies the potential risk to the
                                fetus.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-7523a0aa-35e2-4c13-8a1c-fb8fff31b177">
<id root="42EACC08-F568-6D96-8358-C053C0F92A28" />
<title ID="INV-72936d62-70f2-43db-9777-af43dd8b9266" mediaType="text/x-hl7-title+xml">Labor and Delivery</title>
<text ID="INV-3e328772-99ca-4a10-ad7e-033b2d30bc70"><paragraph ID="INV-834fa7c6-415d-426c-84d4-2dd5f11ecba1">The effect
                                    of ENLON-PLUS on the mother and fetus, on the duration of labor
                                    or delivery, in the possibility that a forceps delivery or other
                                    intervention or resuscitation of the newborn will be necessary,
                                    is not known. The effect of the combination drug on the later
                                    growth, development and functional maturation of the child is
                                    also unknown.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-4431b9a5-153c-4cbc-8822-f54c5f85a96e">
<id root="D47E37CC-DA40-364B-44FA-058D3B040BC9" />
<title ID="INV-e2578672-f6f8-4be7-994e-a109234667c7" mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text ID="INV-a9508654-3d6b-42ea-9342-51b22e642914"><paragraph ID="INV-5d7dadd8-6971-437e-9712-2826f2d505da">The safety
                                    of ENLON-PLUS during lactation in humans has not been
                                    established.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-115fe643-9be3-40e9-884a-270b29bb8a3d">
<id root="4AA5B5E4-D4C7-02CB-E596-77345EB66901" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION" />
<title ID="INV-8bb3b3b6-e6b2-4770-8115-cfb5d4e0833b" mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text ID="INV-539233ba-266f-4810-a097-1648f9154d9c"><paragraph ID="INV-5f9e0583-bdb1-4bbe-80c3-f73ce0753a96">Safety and
                                    effectiveness in pediatric patients have not been established.
                                    Pediatric patients may have increased vagal tone. The effect of
                                    fixed ratios of edrophonium and atropine on heart rate in such
                                    patients has not been evaluated.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-f8521a89-32c8-40b4-97e4-93d7d4cf7971">
<id root="BB8ADD50-0612-C1C5-53DF-151BD766A2BC" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GERIATRIC USE SECTION" />
<title ID="INV-5ed07a33-50ec-4e73-a871-a137343e02bf" mediaType="text/x-hl7-title+xml">Geriatric Use</title>
<text ID="INV-f2aaad42-6669-489e-a702-e4721e5830cd"><paragraph ID="INV-ace9f531-9137-4d6d-a1c7-e6cb3c04d406">Clinical
                                    studies of ENLON-PLUS did not include sufficient numbers of
                                    subjects aged 65 and over to determine whether they respond
                                    differently from younger subjects. Other reported clinical
                                    experience has not identified differences in responses between
                                    the elderly and younger patients. In general, dose selection for
                                    an elderly patient should be cautious, usually starting at the
                                    low end of the dosing range, reflecting the greater frequency of
                                    decreased hepatic, renal, or cardiac function, and of
                                    concomitant disease or other drug therapy.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-751fc2dd-2c8c-481b-9a69-de3421f578c1">
<id root="7FE4F895-7407-DB47-D792-F45FFD6B47A6" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title ID="INV-29fb525a-d64a-4b2e-ae1e-b1615e39b3fc" mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<effectiveTime value="20060309" />
<component>
<section ID="INV-bcc0a993-eeb3-4ee1-9ea0-b466a143a75d">
<id root="5D02FC73-D197-0709-A4CC-24C894CD3190" />
<title ID="INV-1193294e-4bdc-4bfd-9129-25e504e10959" mediaType="text/x-hl7-title+xml">Cardiovascular</title>
<text ID="INV-7d0ceb80-dcb3-443f-8cd5-9763a4d3d88d"><paragraph ID="INV-f223b6d5-7aec-44bc-9f36-7412c8520268">Arrhythmias               Frequency &gt;10%: junctional rhythm, bradycardia,
                                    tachycardia; Frequency 3-10%: first and second degree A-V block,
                                    P Wave changes, atrial premature contractions; Frequency 1-3%:
                                    third degree A-V block, ventricular premature contractions;
                                    Frequency less than 1%: 3 second R-R interval.</paragraph><paragraph ID="INV-e60bd2f9-d7b6-45a1-8fb2-061d3e63eeee">Of the
                                    patients who experienced any arrhythmias, 85% had the onset
                                    within two minutes, 74% no longer had any arrhythmias after 10
                                    minutes. Arrhythmias related to increased vagal tone,
                                    bradycardia, second and third degree heart block respond to
                                    treatment with 0.2-0.4 mg of atropine I.V. (Bigeminy or
                                    ventricular ectopy may be treated with lidocaine 50 mg I.V.).</paragraph><paragraph ID="INV-d2678d7f-87c0-4a33-8a1b-abf2ef3fd9b3">Adverse
                                    experiences reported for anticholinesterase agents such as
                                    edrophonium chloride, but not observed in the 235 patients
                                    studied with ENLON-PLUS (edrophonium chloride, USP and atropine
                                    sulfate, USP) Injection:</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-7c8a13c7-8267-4149-b81a-6c483b828763">
<id root="AF1C2FD0-FF87-F46A-644D-C1E0D2AFE990" />
<title ID="INV-6cb6302b-0230-44e1-ae44-1bc6ad750658" mediaType="text/x-hl7-title+xml">Cardiovascular</title>
<text ID="INV-5689f1fe-a5ba-4f48-85fe-4d862a3c01a5"><paragraph ID="INV-35f7b9ac-c003-48f2-b58c-0cb147bc91fa">Nonspecific
                                    EKG changes, fall in cardiac output leading to
                                hypotension;</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-5dd7d2e9-83e5-4a33-bd5a-135eafcf1f0e">
<id root="15541F92-2941-51B8-0D1B-7D3DBCC82148" />
<title ID="INV-61f06e04-bec9-4718-90d7-ddfec42c793f" mediaType="text/x-hl7-title+xml">Respiratory</title>
<text ID="INV-5cfc874e-235d-4609-ab2f-c26caaf35151"><paragraph ID="INV-5e11da16-e551-4474-98cb-c07a27587f77">Increased
                                    tracheobronchial secretions, laryngospasm, bronchiolar
                                    constriction and respiratory muscle paralysis;</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-89d678cb-98c9-4a5a-abc3-f3703c379e4b">
<id root="FF7BE8C3-793D-B24D-4C35-67424FDF1E47" />
<title ID="INV-9a03d40d-2512-4baf-b812-49d9f27ce7df" mediaType="text/x-hl7-title+xml">Neurologic</title>
<text ID="INV-8b775dd7-60f3-4319-b11e-73a8c5ca313c"><paragraph ID="INV-a66731c6-0831-4b86-a22f-3d8765c85478">Convulsions, dysarthria, dysphonia, and dysphagia;</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-8497af0f-13e6-4d37-bb09-4b6ed8bb5e67">
<id root="275955BB-6EAA-D681-99BC-0E08157B998E" />
<title ID="INV-6db28f74-8a76-409e-a1e3-c28b3222ca30" mediaType="text/x-hl7-title+xml">Gastrointestinal</title>
<text ID="INV-bb31030a-91ca-401f-8bf1-564471b91475"><paragraph ID="INV-e320c0c8-6d91-4a3d-8c72-e23d7d55bab9">Nausea,
                                    vomiting, increased peristalsis, increased gastric and
                                    intestinal secretions, diarrhea, abdominal cramps;</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-1a34c1a5-cdf1-41d8-8ae5-3199cedb677b">
<id root="6FCD8BD0-6FE7-110C-51B2-02CBC306AF38" />
<title ID="INV-0fa1b594-8985-46bd-8870-5d05b0d080a3" mediaType="text/x-hl7-title+xml">Musculoskeletal</title>
<text ID="INV-1b7da627-d6da-4116-9f93-2fc50ce3dce1"><paragraph ID="INV-2b3779c8-ddbc-4248-b2b7-14d5dc32f8fe">Weakness
                                    and fasciculations;</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-352d7dbc-a13a-4b26-9b5d-7c018c8a370d">
<id root="209E72D8-D507-5F4C-B082-FC36EA511774" />
<title ID="INV-3aedaaee-9c2a-460f-a5e5-79dbaa53ce8d" mediaType="text/x-hl7-title+xml">Miscellaneous</title>
<text ID="INV-220f2586-869f-4f60-bd3d-2c3ee52509bd"><paragraph ID="INV-a06f239f-eee1-44f3-9c3d-a3173c330e25">Increased
                                    urinary frequency, diaphoresis, increased lacrimation, pupillary
                                    constriction, diplopia, and conjunctival hyperemia.</paragraph><paragraph ID="INV-f2bef37e-d1aa-4aac-a43f-469c859798bb">Untoward
                                    reactions to atropine sulfate generally are dose-related.
                                    Individual tolerance varies greatly but systemic doses of 0.5 to
                                    10 mg are likely to produce the following effects, which were
                                    not observed in the 235 patients treated with
                                ENLON-PLUS:</paragraph></text>
<effectiveTime value="20060309" />
<component>
<section ID="INV-7a10fbf5-3ceb-4f26-96ff-4e2a1a0bde4e">
<id root="15F2025D-DC3B-9518-C1BE-D581FC88C9B2" />
<title ID="INV-4eb37f7f-a505-47d0-b26b-0cdd3bd5acb0" mediaType="text/x-hl7-title+xml">Neurologic</title>
<text ID="INV-c2a53202-d277-45ed-8b93-d0585dd922fc"><paragraph ID="INV-cd089246-66cf-4df5-be24-3320ecddda64">Speech disturbances and restlessness with
                                        asthenia;</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-4fd312ac-2cc4-4bd9-940d-55d5b395b0d0">
<id root="27B4AFFF-BDFC-9425-13C7-98CFB92F7C5E" />
<title ID="INV-51875ed7-c160-412d-8765-6231e56ef4a8" mediaType="text/x-hl7-title+xml">Dermatologic</title>
<text ID="INV-7d1c0937-67e8-40a7-b587-fe4635c66708"><paragraph ID="INV-cb22731e-7776-4f07-b728-e27329a3c60d">Flushed, dry skin, formation of a scarlatiniform
                                        rash;</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-629e48c8-05c3-41fe-a34c-2b31a1672840">
<id root="92D69FAE-6473-A852-3FB3-B69B6F4F6D7F" />
<title ID="INV-fa1afcd8-7888-4508-ad54-ab496cdd50ee" mediaType="text/x-hl7-title+xml">Miscellaneous</title>
<text ID="INV-c0e44b78-cca8-4239-87c7-ff28993b37d0"><paragraph ID="INV-055e1b59-f027-44ea-92f1-2a79c6aff374">Dryness of the nose and mouth, thirst, blurred vision,
                                            photophobia, slight mydriasis. Atropine may produce
                                            fever through inhibition of heat loss by
                                        evaporation.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="INV-713670b6-e7be-4b03-a6b9-007d9bbb31a3">
<id root="6D78F640-0254-B2DC-5BCA-3209F6E00FCD" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE SECTION" />
<title ID="INV-fed113ed-a724-4999-bf1d-912f70dca0b7" mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<text ID="INV-338b24b0-b8cb-4033-9f42-d89eec39f19e"><paragraph ID="INV-342416ad-80fe-4c82-a173-275f1d2140a2">Muscarinic symptoms
                            (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary
                            secretions and bradycardia) may appear with overdosage (cholinergic
                            crisis) of ENLON-PLUS (edrophonium chloride, USP and atropine sulfate,
                            USP) Injection, but may be managed by the use of additional atropine
                            sulfate. Obstruction of the airway by bronchial secretions can arise and
                            may be managed with suction (especially if tracheostomy has been
                            performed).</paragraph><paragraph ID="INV-517960d6-0e85-46b7-8829-b53ec1002c14">Should edrophonium
                            chloride overdosage occur:</paragraph><list listType="ordered" styleCode="Arabic"><item>Maintain respiratory exchange.</item><item>Monitor cardiac function.</item></list><paragraph ID="INV-932cca93-3bfb-4062-bc61-70f2a4922fb3">Appropriate
                            measures should be taken if convulsions occur or shock is present.</paragraph><paragraph ID="INV-17ce3d6f-e3bf-4051-b439-454be10f166b">Principal
                            manifestations of overdosage (poisoning) with atropine sulfate are
                            delirium, tachycardia and fever. In the treatment of atropine poisoning,
                            respiratory assistance and symptomatic support are indicated. Death is
                            usually due to paralysis of the medullary centers.</paragraph><paragraph ID="INV-0d09af7e-91b8-4e8a-bb6b-82841e539ec0">In the clinical
                            studies performed with ENLON-PLUS, there were no reported overdoses and
                            therefore no clinical information is available regarding overdosing with
                            ENLON-PLUS.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-e1fbc98d-cc18-4bff-9e15-b249a2ba6db5">
<id root="F3B1CF17-9EE2-69CC-E649-88FF818936C1" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title ID="INV-038a8387-5fed-464c-9496-784d31ae871e" mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text ID="INV-314c9b77-0891-4606-8044-338b439b0cbb"><paragraph ID="INV-e7426444-5c19-4143-bb47-8b05f951d5eb">Dosages of
                            ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP)
                            Injection range from 0.05-0.1 mL/kg given slowly over 45 seconds to 1
                            minute at a point of at least 5% recovery of twitch response to
                            neuromuscular stimulation (95% block). The dosage delivered is 0.5-1.0
                            mg/kg of edrophonium chloride and 0.007-0.014 mg/kg of atropine sulfate.
                            A total dosage of 1.0 mg/kg of edrophonium chloride should rarely be
                            exceeded. Response should be monitored carefully and assisted or
                            controlled ventilation secured. Satisfactory reversal permits adequate
                            voluntary respiration and neuromuscular transmission (as tested with a
                            peripheral nerve stimulator). Recurarization has not been reported after
                            satisfactory reversal has been attained.</paragraph><paragraph ID="INV-7576c4b4-2c67-4270-be46-9af3bec94591">Parenteral drug
                            products should be inspected visually for particulate matter and
                            discoloration prior to administration.</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-cc8d5244-73b5-47d7-bd78-19d59dcbdc93">
<id root="E5AA207F-B701-8198-9494-CE6BBEE5BDAB" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title ID="INV-3fd5e511-9c9a-4e3f-8996-088b8df59623" mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text ID="INV-fd0ccd91-ce90-47b1-8a2f-8b7d18153d14"><paragraph ID="INV-4cc15d7b-7cda-48ce-8982-d36308d0ac43">ENLON-PLUS
                            (edrophonium chloride, USP and atropine sulfate, USP) Injection should
                            be stored between 15&#186;-26&#186;C (59&#186;-78&#186;F).</paragraph><paragraph ID="INV-fc151701-f0ab-4cc0-831f-e452b7057af4">NDC 10019-180-05 5
                            mL ampuls, boxes of 10</paragraph><paragraph ID="INV-6704f898-6cec-41be-bd18-0a1062e5babd">NDC 10019-195-15 15
                            mL multidose vials</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
<component>
<section ID="INV-52199364-a0d7-4746-aa70-f6efaae932d9">
<id root="3D770AF2-B2AC-A600-37FC-5031D2EE9064" />
<code code="34093-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="REFERENCES SECTION" />
<title ID="INV-3433ec8c-79ab-4622-998e-34bb6e8b5abf" mediaType="text/x-hl7-title+xml">REFERENCES</title>
<text ID="INV-98dd43bb-46cb-4138-81f1-bef8c7a999d8"><list listType="ordered" styleCode="Arabic"><item>Cronnelly R, Morris RB, Miller RD: Edrophonium: Duration of action
                                and atropine requirement in humans during halothane anesthesia.
                                Anesthesiology 1982;57:261-266.</item><item>Hinderling PH, Gundert-Remy U, Schmidlin O, Heinzel G: Integrated
                                pharmacokinetics and pharmacodynamics of atropine in healthy humans.
                                I: Pharmacokinetics; II: Pharmacodynamics. J Pharmaceutical Sci
                                1985; 74:I-703-710; II-711-717.</item><item>Morris RB, Cronnelly R, Miller RD, Stanski DR, Fahey MR:
                                Pharmacokinetics of edrophonium and neostigmine when antagonizing d-
                                tubocurarine neuromuscular blockade in man. Anesthesiology                   1981;54:399-402.</item><item>Morris RB, Cronnelly R, Miller RD, Stanski DR, Fahey MR:
                                Pharmacokinetics of edrophonium in anephric and renal transplant
                                patients. Br J Anaesth 1981;53:1311-1313.</item><item>Fisher DM, Cronnelly R, Sharma M, Miller RD: Clinical pharmacology
                                of edrophonium in infants and children. Anesthesiology 1984;
                                61:428-433.</item><item>Silverberg PA, Matteo RS, Ornstein E, Young WL, Diaz J:
                                Pharmacokinetics and pharmacodynamics of edrophonium in the elderly.
                                Anesth Analg 1986;65:S142.</item><item>Virtanen R, Kanto J, Iisalo E, Iisalo EU, Salo M, Sjovall S:
                                Pharmacokinetic studies on atropine with special reference to age.
                                Acta Anaesthesiol Scand 1982;26:297-300.</item><item>Back DJ, Calvey TN: Excretion of 14C-edrophonium and its
                                metabolites in bile: role of the liver cell and the peribiliary
                                vascular plexus. Br J Pharmacol., 1972; 44:534.</item></list><paragraph ID="INV-f0cd2bca-58c5-4928-9b65-ff9a630df49a">Baxter and
                            Enlon-Plus are trademarks of Baxter International, Inc.</paragraph><paragraph ID="INV-b2ad241e-4bf6-47b4-9d39-2c99e4490e9e">Manufactured for</paragraph><paragraph ID="INV-4ea8e948-75bc-4da2-bee8-a28831d2af27">Baxter Healthcare
                            Corporation</paragraph><paragraph ID="INV-400cf1b7-4d59-4cca-b06f-7a46fa91a6e2">Deerfield, IL 60015
                            USA</paragraph><paragraph ID="INV-55356bc0-6094-445a-98ae-ac20ac4bed81">by: Taylor
                            Pharmaceuticals</paragraph><paragraph ID="INV-aebda1a3-5615-4384-88b7-10f9bf17704d">Decatur, IL 62525</paragraph><paragraph ID="INV-ad9dde42-2347-43bc-a59f-215ab78c6e63">For Product Inquiry
                            1 800 ANA DRUG (1-800-262-3784)</paragraph><paragraph ID="INV-0cbabaee-521b-4651-8136-94741c410b4e">MLT-47/1.0</paragraph></text>
<effectiveTime value="20060309" />
</section>
</component>
</structuredBody>
</component>
</document>
